CASCADE study
|
Title in German |
Kaskaden-Gentests für erblichen Brust-/Eierstockkrebs und Lynch-Syndrom in der Schweiz. |
|
Title in English |
Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland. |
|
Phase/Biobank/ect. |
Phase 3 |
|
Descriptioin |
The CASCADE study in Switzerland takes place in German, Italian, French and English. Its objectives are: To study hereditary cancer associated with pathogenic variants To address the quality of life, medical and psychosocial needs of families affected by these hereditary cancer syndromes and how these needs change over time To facilitate the coordination of cancer surveillance Providing expert information about the use of cancer genetic services Promoting interventions to help families cope with increased cancer risk and promoting communication about genetic test results Or simply the link About the study - CASCADE Study (swisscascade.ch) |
|
Head Clinical Trial |
|
|
Status |
open to patient recruitment |
|
BASEC Nummer |
NCT03124212 |
|
KOFAM |
37756 |
|
WHO-Register-Nummer |
2016-02052 |
|
Insel-Nummer |
3405 |
Oligocare – EORTC 1811
|
Title in German |
E²-RADIatE: EORTC-ESTRO RADiotherapie InfrAstrukTur für Europa |
|
Title in English |
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe |
|
Description |
This study is being conducted to collect information about radiation treatments. The goal is to link patient information with treatment data and imaging data. The aim is to recognize patterns and identify factors that influence patient care and the success of treatment. |
|
This information can be used to improve standard treatments and learn how to better introduce new technologies into routine practice. The information is used to answer many research questions. Your doctor can inform you about the research question for which your data is being collected. Your data may be used for more than one research question. |
|
|
Phase/Biobank/etc. |
Registerstudie |
|
Head Clinical Trial |
|
|
Status |
active since 23.10.2019 |
|
BASEC-Nummer |
2019-00640 |
|
KOFAM |
keine |
|
WHO-Register-Nummer |
keine |
OligoRARE
|
Title in German |
Gezielte Bestrahlung kleiner neuer metastatischer Läsionen während der Standardbehandlung bei soliden Krebs |
|
Title in English |
Stereotactic body radiotherapy in addition to standard of care treatment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial |
|
Description |
Oligometastasis is generally considered an intermediate state between local and distant metastatic (spreading to the rest of the body) cancer, with a limited number of metastases and organs involved. |
|
Retrospective studies (studies of patients who have been treated in the past) have shown that aggressive treatment (surgery or radiation) of metastases added to standard systemic therapy achieved longer survival in about a quarter of patients. |
|
|
Technical developments in radiation therapy now make it possible to deliver targeted high doses of radiation. This so-called stereotactic radiation therapy (SBRT) has become the standard for oligometastatic disease, treating different anatomical sites (e.g. lung and liver). In addition, SBRT is a non-invasive treatment that is carried out in a few outpatient sessions and therefore allows systemic therapy to be continued. |
|
|
OligoRare is aimed at patients with oligometastases of all solid cancers except lung, breast, colon and prostate. The primary objective is to assess whether adding SBRT to standard of care improves overall survival in patients with “oligometastatic rare” cancers. Patients with a maximum of 5 oligometastases are treated according to standard of care with or without the addition of SBRT. The standard includes chemotherapy, targeted therapy (agents that specifically attack cancer cells), hormone therapy, immunotherapy (agents that stimulate the body's natural defenses), or observation. Patients will be followed every 3 months for the first 2 years and every 6 months for the next 3 years. |
|
|
Phase/Biobank/etc. |
Phase III |
|
Head Clinical Trial |
|
|
Status |
active since August 2021 |
|
BASEC-Nummer |
2021-00693 |
|
KOFAM |
SNCTP000004459 |
|
WHO-Register-Nummer |
NCT04498767 |
SMILE
|
Title in German |
Vergleich zweier Bestrahlungsschemata zur Behandlung von Knochenmetastasen ausserhalb der Wirbelsäule |
|
Title in English |
Stereotactic multiple fraction radiotherapy for non-spine bone metastases - SMILE |
|
Description |
With this study we want to investigate whether high-precision radiotherapy over 3 sessions with 9 Gy per session within a week works as well as high-precision radiotherapy over 5 sessions with 7 Gy per session within a week. |
|
Phase/Biobank etc. |
|
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
Aktive since 07.12.2022 |
|
BASEC Nummer |
2022-00631 |
|
KOFAM |
SNCTP000004897 |
|
WHO-Register-Nummer |
NCT05406063 |
|
Insel-Nummer |
STREAM
|
Title in German |
STREAM – Statin-Stopp bei älteren Personen ohne vorbestehenden Herzinfarkt oder Schlaganfall |
|
Title in English |
Discontinuing Statins in Multimorbid Older Adults without Cardiovascular Disease (STREAM) – a randomized non-inferiority clinical trial |
|
Description |
STREAM is a Swiss-wide, randomized clinical study that examines the influence of stopping statin therapy on quality of life, drug side effects, the risk of falls and the risk of heart attack or stroke in people over 70 years of age without a pre-existing heart attack/stroke. The study is continuously monitored by an independent committee to ensure patient safety. |
|
Phase/Biobank etc. |
– |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
active since 01.11.2021 |
|
BASEC Nummer |
2021-01513 |
|
KOFAM |
|
|
WHO-Register-Nummer |
NCT05178420 (ClinicalTrials.gov) |
|
Insel-Nummer |
4912 |